The Latest Breaking News from AbbVie

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

By investing in these dividend powerhouses, investors can achieve reliable income, mitigate risk through diversification, and potentially enjoy capital gains.

The Federal Reserve cut rates again at its December meeting, and lower borrowing costs could boost these large-cap stocks.

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

These companies have consistently paid and increased their dividends, and they have a growing earnings base to support their future payouts.

A high yield doesn't necessarily translate to a buy. This article bridges the gap by combining high dividend payouts and buy ratings.

This week we have Tesla (TSLA), Microsoft (MSFT), Alphabet (GOOGL), Exxon Mobil (XOM), Visa (V), Abbvie (ABBV) and Chipotle Mexican Grill (CMG) all set to report.

AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.